---
title: "Predictive Oncology Inc. Reports Q1 2025 Loss of $2.3 Million on Revenue of $110,310"
description: "Predictive Oncology Inc. reported a Q1 2025 loss of $2.3 million on revenue of $110,310, a significant increase from $4,858 in Q1 2024. The revenue growth was driven by the completion of a tumor-speci"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/240356312.md"
published_at: "2025-05-15T11:04:51.000Z"
---

# Predictive Oncology Inc. Reports Q1 2025 Loss of $2.3 Million on Revenue of $110,310

> Predictive Oncology Inc. reported a Q1 2025 loss of $2.3 million on revenue of $110,310, a significant increase from $4,858 in Q1 2024. The revenue growth was driven by the completion of a tumor-specific 3D model. The company ended the quarter with $3.1 million in cash, up from $611,822 at the end of 2024. Predictive Oncology also partnered with Tecan Group to enhance drug screening capabilities and is seeking collaborations with biopharmaceutical firms for drug repurposing using AI and machine learning.

Predictive Oncology Inc. (Nasdaq: POAI) reported its financial results for the first quarter of 2025, ending March 31. The company recorded total revenue of $110,310, a significant increase from the $4,858 reported during the same period in 2024. This rise in revenue was primarily attributed to the completion of a tumor-specific 3D model within the quarter. The company reported a loss from continuing operations of approximately $2.3 million. Basic and diluted loss per common share from continuing operations for the quarter was $0.32, compared to $0.88 for the same period in 2024. Predictive Oncology concluded the quarter with $3.1 million in cash and cash equivalents, a substantial increase from $611,822 as of December 31, 2024. The company also reported an improved Stockholder's Deficit compared to December 31, 2024. During the first three months of 2025, Predictive Oncology received more than $3.1 million in combined gross proceeds from the sale to DeRoyal and issuance of common stock. The company also partnered with Switzerland-based Tecan Group Ltd. to expand high-throughput drug screening capabilities, which was showcased at the 2025 Society for Laboratory Automation and Screening International Conference & Exhibition in San Diego, CA. The company is exploring potential partnerships with leading biopharmaceutical companies to leverage its artificial intelligence and machine learning platform for drug repurposing in new cancer indications.

### Related Stocks

- [POAI.US - Predictive Oncology](https://longbridge.com/en/quote/POAI.US.md)
- [AGPU.US - Axe Compute](https://longbridge.com/en/quote/AGPU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Axe Compute Inc. ernennt Christopher Miglino zum neuen CEO | Axe Compute Inc. has appointed Christopher Miglino as the new Chief Executive Officer. Miglino will lead the company wit | [Link](https://longbridge.com/en/news/275320870.md) |
| Axe Compute Inc. Directors and Chief Investment Officer Resign | Axe Compute Inc. announced the resignations of three key personnel: Shawn Matthews as director effective January 15, 202 | [Link](https://longbridge.com/en/news/273428740.md) |
| Axe Compute Inc. Sponsors Sequire Investor Summit Puerto Rico | Axe Compute Inc. (NASDAQ: AGPU) will sponsor the Sequire Investor Summit Puerto Rico 2026, scheduled for January 20-22,  | [Link](https://longbridge.com/en/news/272282563.md) |
| Predictive Oncology Rebrands to Axe Compute Inc. on Nasdaq | Predictive Oncology has rebranded to Axe Compute Inc. and started trading on Nasdaq under the ticker AGPU. The company i | [Link](https://longbridge.com/en/news/269577140.md) |
| Predictive Oncology Inc. Held Shareholder Meeting and Approved Key Proposals | Predictive Oncology Inc. held its Annual Meeting of Stockholders, approving all agenda proposals. Daniel E. Handley and  | [Link](https://longbridge.com/en/news/267415999.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
